Payment overview · 2025
General Payments
$1,073.80
51 reported records · 20 companies
Healthcare provider profile · identity verified
James J Crosswell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BEAUFORT, NC · NPI 1407900673
Verified facts
What the public records show
CMS Open Payments records show James J Crosswell, MD received $1,073.80 in general payments during 2025 across 51 reported records.
Lilly USA, LLC accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 565 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.01 | 16.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.24 | 16.0% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $128.26 | 11.9% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$102.93 | 9.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.42 | 7.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.17 | 6.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.44 | 3.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.83 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.56 | 3.2% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $34.27 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.27 | 3.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.15 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.71 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.76 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.94 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.92 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.93 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.76 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.84 | 1.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.39 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,073.80 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $147.09 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $128.26 | 6 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $102.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.42 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.42 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.17 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.17 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.72 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $34.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.06 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 565 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 237 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 128 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
237 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
128 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
565 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 1195 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1074 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1072 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 856 | 107 |
| Trazodone Hcl | Trazodone Hcl | 782 | 84 |
| Furosemide | Furosemide | 745 | 72 |
| Gabapentin | Gabapentin | 731 | 77 |
| Valsartan | Valsartan | 625 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 624 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 604 | 69 |
| Potassium Chloride | Potassium Chloride | 583 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 581 | 40 |
| Lisinopril | Lisinopril | 574 | 84 |
| Eliquis | Apixaban | 565 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 524 | 88 |
| Sertraline Hcl | Sertraline Hcl | 521 | 33 |
| Losartan Potassium | Losartan Potassium | 500 | 113 |
| Alprazolam | Alprazolam | 397 | 61 |
| Divalproex Sodium | Divalproex Sodium | 383 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 354 | 65 |
| Carvedilol | Carvedilol | 346 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 346 | 58 |
| Buspirone Hcl | Buspirone Hcl | 307 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 304 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 51 |
| Famotidine | Famotidine | 282 | 45 |
| Montelukast Sodium | Montelukast Sodium | 267 | 30 |
| Lorazepam | Lorazepam | 258 | 40 |
| Mirtazapine | Mirtazapine | 246 | 23 |
| Farxiga | Dapagliflozin Propanediol | 237 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 32 |
| Tramadol Hcl | Tramadol Hcl | 228 | 61 |
| Prednisone | Prednisone | 208 | 79 |
| Sucralfate | Sucralfate | 206 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 205 | 19 |
| Finasteride | Finasteride | 199 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 195 | 17 |
| Simvastatin | Simvastatin | 179 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 19 |
| Metformin Hcl | Metformin Hcl | 170 | 47 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 169 | 28 |
| Olanzapine | Olanzapine | 168 | suppressed |
| Xarelto | Rivaroxaban | 168 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 164 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 163 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 159 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 159 | 13 |
| Jardiance | Empagliflozin | 152 | 26 |
| Torsemide | Torsemide | 152 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 141 | 27 |
| Ezetimibe | Ezetimibe | 138 | 35 |
| Levetiracetam | Levetiracetam | 136 | suppressed |
| Allopurinol | Allopurinol | 133 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 129 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 21 |
| Atenolol | Atenolol | 124 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 124 | 31 |
| Ozempic | Semaglutide | 124 | 27 |
| Movantik | Naloxegol Oxalate | 122 | suppressed |
| Diazepam | Diazepam | 118 | 17 |
| Bupropion Xl | Bupropion Hcl | 115 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 113 | suppressed |
| Azithromycin | Azithromycin | 111 | 75 |
| Donepezil Hcl | Donepezil Hcl | 111 | 18 |
| Entresto | Sacubitril/Valsartan | 107 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 37 |
| Methenamine Hippurate | Methenamine Hippurate | 106 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 36 |
| Myrbetriq | Mirabegron | 104 | 14 |
| Metformin Hcl Er | Metformin Hcl | 103 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 101 | 40 |
| Trulicity | Dulaglutide | 100 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 23 |
| Glimepiride | Glimepiride | 93 | 30 |
| Spironolactone | Spironolactone | 91 | 18 |
| Baclofen | Baclofen | 90 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 89 | suppressed |
| Clonazepam | Clonazepam | 87 | 14 |
| Pregabalin | Pregabalin | 86 | 16 |
| Methocarbamol | Methocarbamol | 83 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 83 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 82 | suppressed |
| Ranolazine Er | Ranolazine | 80 | suppressed |
| Aripiprazole | Aripiprazole | 78 | suppressed |
| Celecoxib | Celecoxib | 77 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 77 | 14 |
| Bupropion Hcl | Bupropion Hcl | 73 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 24 |
| Ibuprofen | Ibuprofen | 72 | 22 |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Synthroid | Levothyroxine Sodium | 68 | 12 |
| Cilostazol | Cilostazol | 67 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 66 | suppressed |
| Linzess | Linaclotide | 65 | 11 |
| Fluconazole | Fluconazole | 63 | 29 |
| Meloxicam | Meloxicam | 63 | 13 |
| Prazosin Hcl | Prazosin Hcl | 61 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 59 | 41 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Risperidone | Risperidone | 55 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 53 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 16 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | suppressed |
| Fentanyl | Fentanyl | 47 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 45 | 11 |
| Haloperidol | Haloperidol | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Nystatin | Nystatin | 43 | 23 |
| Chlorthalidone | Chlorthalidone | 42 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 24 |
| Nyamyc | Nystatin | 36 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 27 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 17 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 13 |
| Estradiol | Estradiol | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | 13 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,073.80 · 51 records | Lilly USA, LLC | AIRSUPRA, APLIGRAF, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, KISUNLA, KYPHON EXPRESS II KYPHOPAK TRAY, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error